MedTrace Logo

Risk Factors , Types and Neuroimaging Findings in Patients With Cerebral Palsy at Assiut University Children's Hospital

NCT06928012 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-04-15

No results posted yet for this study

Summary

Cerebral palsy (CP) is the most common motor disorder among children as its worldwide prevalence is ranging from 1.5 to more than 4 per 1000 live births or children of a defined age range.

* Pediatric cerebral palsy is a clinical syndrome caused by brain injury or lesions in children from before birth to 1 month after birth, and mainly manifests as non progressive central dyskinesia and abnormal posture.
* Research has shown that the prevalence of cerebral palsy in children worldwide is about 3.16% , and results in heavy familial and social burdens as well as usage of medical resources, Despite considerable research , the complex etiology and pathogenesis of cerebral palsy remain unclear. The high-risk factors of cerebral palsy are complex and diverse (CP) appeared to be more prevalent in low- or middle-income countries than in high-income countries.

(CP) prevalence was about 3.6 and 2.9 per 1000 children in Uganda and Egypt, respectively, but the prevalence was 1.8 to 2.3 cases per 1000 children in the USA, Europe, and Australia.

-Cerebral palsy (CP) describes a group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. It begins in early childhood and persists through the lifespan.

It was first reported as a movement disorder in the historical documents of the Sumerians, and Hippocrates.

-Cerebral palsy (CP) is the major cause of motor impairment in young children, The clinical picture changes over time, and a recent review showed that referral for diagnosis typically happens between 10 and 21 months of age.

Conditions

  • Cerebral Palsy

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
6 Months
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-05-01
Completion
2026-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06928012 on ClinicalTrials.gov